199 related articles for article (PubMed ID: 8657107)
1. Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo.
Caamaño JH; Perez P; Lira SA; Bravo R
Mol Cell Biol; 1996 Apr; 16(4):1342-8. PubMed ID: 8657107
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites.
Franzoso G; Bours V; Azarenko V; Park S; Tomita-Yamaguchi M; Kanno T; Brown K; Siebenlist U
EMBO J; 1993 Oct; 12(10):3893-901. PubMed ID: 8404857
[TBL] [Abstract][Full Text] [Related]
3. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.
Dechend R; Hirano F; Lehmann K; Heissmeyer V; Ansieau S; Wulczyn FG; Scheidereit C; Leutz A
Oncogene; 1999 Jun; 18(22):3316-23. PubMed ID: 10362352
[TBL] [Abstract][Full Text] [Related]
4. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner.
Nolan GP; Fujita T; Bhatia K; Huppi C; Liou HC; Scott ML; Baltimore D
Mol Cell Biol; 1993 Jun; 13(6):3557-66. PubMed ID: 8497270
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the human P-selectin promoter by Bcl-3 and specific homodimeric members of the NF-kappa B/Rel family.
Pan J; McEver RP
J Biol Chem; 1995 Sep; 270(39):23077-83. PubMed ID: 7559449
[TBL] [Abstract][Full Text] [Related]
6. Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA.
Bundy DL; McKeithan TW
J Biol Chem; 1997 Dec; 272(52):33132-9. PubMed ID: 9407099
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis.
Budunova IV; Perez P; Vaden VR; Spiegelman VS; Slaga TJ; Jorcano JL
Oncogene; 1999 Dec; 18(52):7423-31. PubMed ID: 10602501
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene.
Kurland JF; Kodym R; Story MD; Spurgers KB; McDonnell TJ; Meyn RE
J Biol Chem; 2001 Nov; 276(48):45380-6. PubMed ID: 11567031
[TBL] [Abstract][Full Text] [Related]
9. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition.
Franzoso G; Bours V; Park S; Tomita-Yamaguchi M; Kelly K; Siebenlist U
Nature; 1992 Sep; 359(6393):339-42. PubMed ID: 1406939
[TBL] [Abstract][Full Text] [Related]
10. NF- kappa B2/p100 induces Bcl-2 expression.
Viatour P; Bentires-Alj M; Chariot A; Deregowski V; de Leval L; Merville MP; Bours V
Leukemia; 2003 Jul; 17(7):1349-56. PubMed ID: 12835724
[TBL] [Abstract][Full Text] [Related]
11. BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages.
Wessells J; Baer M; Young HA; Claudio E; Brown K; Siebenlist U; Johnson PF
J Biol Chem; 2004 Nov; 279(48):49995-50003. PubMed ID: 15465827
[TBL] [Abstract][Full Text] [Related]
12. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence.
Pratt MA; Bishop TE; White D; Yasvinski G; Ménard M; Niu MY; Clarke R
Mol Cell Biol; 2003 Oct; 23(19):6887-900. PubMed ID: 12972607
[TBL] [Abstract][Full Text] [Related]
13. Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation.
Watanabe N; Iwamura T; Shinoda T; Fujita T
EMBO J; 1997 Jun; 16(12):3609-20. PubMed ID: 9218802
[TBL] [Abstract][Full Text] [Related]
14. BCL-6 negatively regulates expression of the NF-kappaB1 p105/p50 subunit.
Li Z; Wang X; Yu RY; Ding BB; Yu JJ; Dai XM; Naganuma A; Stanley ER; Ye BH
J Immunol; 2005 Jan; 174(1):205-14. PubMed ID: 15611242
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the C-terminal region of p105 with the nuclear localisation signal of p50 is required for inhibition of NF-kappa B DNA binding activity.
Matthews JR; Watson E; Buckley S; Hay RT
Nucleic Acids Res; 1993 Sep; 21(19):4516-23. PubMed ID: 7694229
[TBL] [Abstract][Full Text] [Related]
16. Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen.
Weih F; Carrasco D; Bravo R
Oncogene; 1994 Nov; 9(11):3289-97. PubMed ID: 7936653
[TBL] [Abstract][Full Text] [Related]
17. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers.
Fujita T; Nolan GP; Liou HC; Scott ML; Baltimore D
Genes Dev; 1993 Jul; 7(7B):1354-63. PubMed ID: 8330739
[TBL] [Abstract][Full Text] [Related]
18. Mapping the Interaction of B Cell Leukemia 3 (BCL-3) and Nuclear Factor κB (NF-κB) p50 Identifies a BCL-3-mimetic Anti-inflammatory Peptide.
Collins PE; Grassia G; Colleran A; Kiely PA; Ialenti A; Maffia P; Carmody RJ
J Biol Chem; 2015 Jun; 290(25):15687-15696. PubMed ID: 25922067
[TBL] [Abstract][Full Text] [Related]
19. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma.
Thornburg NJ; Pathmanathan R; Raab-Traub N
Cancer Res; 2003 Dec; 63(23):8293-301. PubMed ID: 14678988
[TBL] [Abstract][Full Text] [Related]
20. The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding.
Hatada EN; Nieters A; Wulczyn FG; Naumann M; Meyer R; Nucifora G; McKeithan TW; Scheidereit C
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2489-93. PubMed ID: 1532257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
